Free Trial

Quoin Pharmaceuticals Q2 2024 Earnings Report

Quoin Pharmaceuticals logo
$0.24 -0.04 (-15.16%)
As of 03/28/2025 03:58 PM Eastern

Quoin Pharmaceuticals EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.75
Beat/Miss
Beat by +$0.36
One Year Ago EPS
-$2.13

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Quoin Pharmaceuticals Earnings Headlines

FY2025 Earnings Forecast for QNRX Issued By Zacks Small Cap
Wall Street’s “AI Oracle” Reveals Next Big Tech Play
A tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Oracle"—known for spotting Apple, Amazon, and Google early—has identified a firm with patented tech that could become essential to every major AI player. He shares the name and ticker in this free video—but warns the opportunity could vanish once it hits the mainstream.
What is Zacks Small Cap's Forecast for QNRX Q1 Earnings?
Quoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last year
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

View Quoin Pharmaceuticals Profile

More Earnings Resources from MarketBeat